Cancer Chemical Biology and Metabolism Training Program

项目概要/摘要 丹娜-法伯癌症研究所（DFCI）的教师正在申请资金，以支持一个新的，综合的， 博士后培训计划在癌症化学生物学和代谢（CCBM）-两个协同和 概念上相关的研究学科扎根于小分子化学和生物化学， 从基础研究和转化研究的角度来看越来越重要。该方案的目标是： 1)提供与癌症化学生物学和代谢相关的广泛主题的培训，例如 临床前癌症靶点验证，化学筛选，基于结构的药物发现，肿瘤代谢， 肿瘤和宿主代谢之间的相互作用，细胞生物能量学和代谢组学， 生物化学，蛋白质组学和化学蛋白质组学，以及动物肿瘤建模; 2）使受训者熟悉国家- 化学生物学和代谢科学的最先进技术和方法，3）培训研究员识别 重要的问题和方法，将推动该领域的发展，并提供转化的机会， 影响癌症治疗; 4）为学员提供机会，发展和提高他们的能力 和科学沟通技能; 5）通过以下方式指导研究员走向独立的科学职业生涯： 实施个人发展计划（IDPs），个人博士后指导委员会， 为学员提供量身定制的机会，根据他们的情况获得辅导和教学经验。 职业目标。 CCBM培训计划每年将支持8名博士后研究员，为期2年。将 由主任（托马斯罗伯茨博士，联系PD/PI）和联合主任（Nika Danial博士，PD/PI）管理， 将包括来自DFCI 4个部门的26名导师和6名共同导师。项目负责人及合作伙伴 主任将与培训监督委员会（TOC）、外部咨询委员会（EAB）和 由受训者领导的咨询小组，由现任和前任计划研究员组成，他们将帮助确定如何 优化方案。衡量学员满意度、量化成果和评估的其他策略 该计划的有效性将包括对受训人员和导师的年度调查，以及退出和 校友访谈通过最先进的核心设施和技术平台提供机构支持，以及 因为支持T32特定培训活动和年度EAB会议的资金将大大提高 培训计划。除了在各种科学和职业发展方面提供强有力的培训外， 技能，该方案的一个关键目标是招募和支持更多样化的受训者群体。进一步确保 该计划在提高多样性方面的有效性，我们的EAB和培训监督委员会包括领导人 在多样性和包容性方面有着丰富的经验。我们相信，综合CCBM培训计划将 为一系列研究职业做好准备，并培养下一代科学家，他们将在未来的研究中茁壮成长。 21世纪世纪的生物医学劳动力，将在癌症研究和治疗方面取得突破。 !

Project Summary/Abstract The faculty of the Dana-Farber Cancer Institute (DFCI) is requesting funds to support a new, integrative, postdoctoral training program in Cancer Chemical Biology and Metabolism (CCBM) — two synergistic and conceptually related research disciplines grounded in small molecule chemistry and biochemistry that are of growing importance from both basic and translational research perspectives. The goals of this program are to: 1) provide training in a wide range of topics relevant to cancer chemical biology and metabolism such as preclinical cancer target validation, chemical screens, structure-based drug discovery, tumor metabolism, cross-talk between tumor and host metabolism, cellular bioenergetics and metabolomics, mechanistic biochemistry, proteomics and chemoproteomics, and animal tumor modelling; 2) familiarize trainees with state- of-the-art technologies and approaches in chemical biology and metabolic science, 3) train fellows to identify important questions and approaches that will move the field forward and provide translational opportunities to impact cancer treatment; 4) provide trainees with opportunities to develop and enhance their grantsmanship and scientific communication skills; 5) coach fellows on their paths to independent careers in science by implementing Individual Development Plans (IDPs), individual postdoctoral mentoring committees, and customized opportunities for trainees to acquire experience in mentoring and teaching depending on their career goals. The CCBM Training Program will support 8 postdoctoral fellows per year for 2-year appointments. It will be administered by a Director (Dr. Thomas Roberts, Contact PD/PI) and a co-Director (Dr. Nika Danial, PD/PI), and will include 26 mentors and 6 co-mentors from 4 departments at DFCI. The program Director and co- Director will work closely with a Training Oversight Committee (TOC), an External Advisory Board (EAB), and a trainee-led advisory group consisting of current and past program fellows who will help identify ways to optimize the program. Additional strategies to measure trainee satisfaction, quantify outcomes, and evaluate the effectiveness of the program will include annual surveys from trainees and mentors, as well as exit and alumni interviews. Institutional support through state-of-the-art core facilities and technology platforms, as well as funds to support T32-specific training activities and yearly EAB meetings will significantly enhance the training program. In addition to offering robust training in a diverse range of scientific and career development skills, a key goal of the program is to recruit and support a more diverse group of trainees. To further ensure the program's effectiveness in enhancing diversity, our EAB and Training Oversight Committee include leaders with deep experience in diversity and inclusion. We believe the integrative CCBM Training Program will prepare fellows for a range of research careers and train the next generation of scientists who will thrive in the 21st century biomedical workforce that will make breakthroughs in cancer research and treatment. !